ABSORPTION OF ELLAGITANNINS FROM DIETARY SOURCES

从膳食中吸收鞣花单宁

基本信息

  • 批准号:
    2012139
  • 负责人:
  • 金额:
    $ 3.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-05-15 至 1999-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: The long term goal of this project is to determine if hydrolyzable ellagitannins present in dietary sources prevent cancer in humans. The more immediate purpose of this project is to assess the a b s o r ption and metabolism of hydrolyzable ellagitannins present in raspberries, strawberries and walnuts by the human digestive system. We believe that the hydrolyzable ellagitannins are absorbed into the human blood stream and metabolized after raspberries, strawberries and walnuts are consumed. We also believe that these ellagitannins and metabolites can be identified and quantified. The purpose for doing this is to identify biologically active ellagitannins and metabolites for further cell and animal chemoprevention studies. This study will also identify which dietary source delivers the highest concentration of biologically active ellagitannins to the blood stream, which will be useful for continuing human chemoprevention clinical trials. In order to identify and quantify the ellagitannins absorbed into the blood stream after raspberries, strawberries, and walnuts are consumed, thirty healthy volunteers will be broken into three equal groups and admitted to the MUSC General Clinical Research Center. After baseline urine and serum samples are obtained, the volunteers will be fed a known quantity of either raspberries, strawberries or walnuts under controlled conditions. Urine will be collected and a serial blood draw will be taken from each volunteer over the 24-hour study period. Known ellagitannins will then be identified and quantified in the blood and urine by HPLC. Unknown ellagitannins and ellagitannin metabolites will be isolated by HPLC and submitted for Mass Spectrum (FAB), NMR, UV and FR-IR analysis so that structural determinations can be made.
描述:这个项目的长期目标是确定是否

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANIEL W NIXON其他文献

DANIEL W NIXON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANIEL W NIXON', 18)}}的其他基金

START- STRATEGIC TIMING OF ANTIRETROVIRAL THERAPY
开始——抗逆转录病毒治疗的战略时机
  • 批准号:
    8166579
  • 财政年份:
    2009
  • 资助金额:
    $ 3.89万
  • 项目类别:
STUDY A5235: A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN THE
研究 A5235:米诺环素的 II 期、随机、双盲研究
  • 批准号:
    8166560
  • 财政年份:
    2009
  • 资助金额:
    $ 3.89万
  • 项目类别:
CLINICAL TRIAL: A PHASE III COMPARATIVE STUDY OF THREE NON-NUCLEOSIDE REVERSE TR
临床试验:三种非核苷反向TR的III期比较研究
  • 批准号:
    8166580
  • 财政年份:
    2009
  • 资助金额:
    $ 3.89万
  • 项目类别:
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/
临床试验:皮下重组 IL-2 在患者中的 III 期研究
  • 批准号:
    7950848
  • 财政年份:
    2008
  • 资助金额:
    $ 3.89万
  • 项目类别:
AN INTERNATIONAL, PHASE II, MULTI-SITE, OPEN-LABEL, RANDOMIZED STUDY OF ALDES
ALDES 的国际、II 期、多中心、开放标签、随机研究
  • 批准号:
    7717048
  • 财政年份:
    2007
  • 资助金额:
    $ 3.89万
  • 项目类别:
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/
临床试验:皮下重组 IL-2 在患者中的 III 期研究
  • 批准号:
    7717012
  • 财政年份:
    2007
  • 资助金额:
    $ 3.89万
  • 项目类别:
NUTRITIONAL INTAKE, HORMONE LEVELS, ENERGY BALANCE AND BREAST CANCER NATURAL HX
营养摄入量、激素水平、能量平衡和乳腺癌 NATURAL HX
  • 批准号:
    6119059
  • 财政年份:
    1998
  • 资助金额:
    $ 3.89万
  • 项目类别:
ELLAGITANNINS & CANCER PREVENTION
鞣花单宁
  • 批准号:
    6265478
  • 财政年份:
    1998
  • 资助金额:
    $ 3.89万
  • 项目类别:
BIOAVAILABILITY STUDY OF ELLAGIC ACID FROM DIETARY INTAKE OF RASPBERRIES
覆盆子膳食摄入中鞣花酸的生物利用度研究
  • 批准号:
    6250279
  • 财政年份:
    1997
  • 资助金额:
    $ 3.89万
  • 项目类别:
NUTRITIONAL INTAKE, HORMONE LEVELS, ENERGY BALANCE AND BREAST CANCER NATURAL HX
营养摄入量、激素水平、能量平衡和乳腺癌 NATURAL HX
  • 批准号:
    6250289
  • 财政年份:
    1997
  • 资助金额:
    $ 3.89万
  • 项目类别:

相似海外基金

MRI: Acquisition of an X-ray Diffractometer for Research and Training in Chemical Structure-Function Studies
MRI:购买 X 射线衍射仪用于化学结构-功能研究的研究和培训
  • 批准号:
    1726630
  • 财政年份:
    2017
  • 资助金额:
    $ 3.89万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了